Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, November 19, 2015
Charles River Laboratories International has acquired Oncotest GmbH, a Freiburg, Germany-based contract research organization (CRO) providing discovery services for oncology, one of the largest therapeutic areas for biopharmaceutical research and ...
read more
Wednesday, April 06, 2022
Charles River Laboratories International, Inc. has acquired Explora BioLabs Holdings, Inc., a provider of contract vivarium research services.
read more
Charles River Laboratories has acquired Blue Stream Laboratories, Inc. Combining Blue Stream with Charles River’s existing discovery, safety assessment, and biologics capabilities creates a leading provider with the ability to support biologic and ...
read more
Tuesday, January 31, 2023
Charles River Laboratories International has acquired SAMDI Tech, Inc, a provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research. The acquisition marks the culmination of a partnership between the ...
read more
Wednesday, January 17, 2018
Charles River Laboratories announced the appointment of Jean-Paul Mangeolle, former President of AB SCIEX, to its Board of Directors.
read more
Wednesday, October 02, 2019
Charles River announced the appointment of Virginia M. Wilson, the recently retired Senior Executive Vice President and Chief Financial Officer of TIAA, to its Board of Directors.
read more
Charles River Laboratories International, an early-stage contract research organization (CRO), has extended its longstanding, strategic, integrated drug discovery partnership with Chiesi Farmaceutici SpA in the field of respiratory disease.
read more
Charles River Laboratories International has entered into a strategic partnership with BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development.
read more
Wednesday, August 08, 2018
For the quarter, revenue from continuing operations was $585.3 million, an increase of 24.8% from $469.1 million in the second quarter of 2017.
read more
Charles River Laboratories International, Inc. has reported its results for the first quarter of 2016. For the quarter, revenue from continuing operations was $354.9 million, an increase of 10.8% from $320.4 million in the first quarter of 2016.
read more
Tuesday, February 13, 2018
Charles River Laboratories announced two new executive management appointments.
read more
Thursday, August 24, 2023
Charles River Laboratories International, Inc. announced a High Quality (HQ) plasmid manufacturing collaboration with Fondazione Telethon.
read more
Charles River Laboratories International Inc. announced a long-term solar energy contract to address the entirety of the Company’s North American electric power requirements with clean, renewable energy by 2023. Charles River and Duke Energy ...
read more
Thursday, October 14, 2021
Charles River Laboratories International announced that it has divested its Research Models and Services operations in Japan (RMS Japan) and its gene therapy CDMO site in Sweden (CDMO Sweden) in two separate transactions.
read more
Wednesday, April 16, 2014
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus. The ...
read more